Add as a preferred source on GooglePharmaCyte Biotech Board Approves 1-for-19 Reverse Stock Split
The split is intended to help the company meet Nasdaq's minimum bid price requirement for continued listing. Split-adjusted trading is scheduled to begin Nov. 13.
The board of PharmaCyte Biotech, Inc. approved a 1-for-19 reverse stock split to raise the company's per-share trading price and regain compliance with Nasdaq's minimum bid price requirement for continued listing.
Under the split, 19 existing common shares will convert into one share. Stockholders approved the authority for the split at the company's March 30 annual meeting.
The split is legally effective Nov. 12 at 4:01 p.m. ET (21:01 UTC). Split-adjusted trading is scheduled to begin Nov. 13.
John Kim
John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.